information: Initiation of development program
Announcement: initiation of development program
Company: BioInvent (Sweden)
Product: BI-1607 (anti FcgammaRllB antibody/anti-PD1 antibody)
mechanism: monclonal antibody/immune checkpoint inhibitor
Disease: solid tumors
area: Cancer - Oncology
- • On October 16, 2018, BioInvent announced its intention to initiate three new clinical programs in solid cancer. In addition to the previously disclosed programs (BI-1206 + rituximab – projected topline results H1 2020; and the Transgene and Pfizer collaborations), and subject to successful preclinical results and sufficient financial resources, BioInvent intends to advance BI-1607, the anti FcgammaRllB antibody/anti-PD1 antibody program in solid cancer (projected start phase l/lla in H1 2019).